Cost of Revenue: Key Insights for Vericel Corporation and Taro Pharmaceutical Industries Ltd.

Comparing Cost Dynamics: Vericel vs. Taro (2014-2023)

__timestampTaro Pharmaceutical Industries Ltd.Vericel Corporation
Wednesday, January 1, 201417927900017293000
Thursday, January 1, 201518635900026470000
Friday, January 1, 201617178500028307000
Sunday, January 1, 201720813600030354000
Monday, January 1, 201819840500032160000
Tuesday, January 1, 201922416900037571000
Wednesday, January 1, 202024504400039951000
Friday, January 1, 202125231400050159000
Saturday, January 1, 202226822500054577000
Sunday, January 1, 202330462900061940000
Monday, January 1, 2024324203000
Loading chart...

Unveiling the hidden dimensions of data

Cost of Revenue Trends: Vericel Corporation vs. Taro Pharmaceutical Industries Ltd.

In the ever-evolving pharmaceutical landscape, understanding cost dynamics is crucial. From 2014 to 2023, Taro Pharmaceutical Industries Ltd. consistently outpaced Vericel Corporation in cost of revenue, with Taro's costs peaking at over 320 million in 2023, marking an impressive 81% increase from 2014. In contrast, Vericel's costs grew by 258% over the same period, reaching approximately 62 million in 2023. This stark difference highlights Taro's larger scale of operations. However, Vericel's rapid growth trajectory suggests a strategic expansion. Notably, data for 2024 is incomplete, indicating potential shifts in the coming year. These insights provide a window into the financial strategies of these companies, offering investors a glimpse into their operational efficiencies and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025